Cargando…
Case Report: Targeted Therapy with Anlotinib for a Rare Case of Spinal Cord Glioblastoma with FGFR3 Mutation
Primary spinal cord glioblastoma (PSC GBM) is a rare disease with limited treatment options. Here, we describe a case of PSC GBM treated with anlotinib in this report. Molecular characterization confirmed the presence of the MGMT promoter unmethylated, IDH wild type, FGFR3 p.S249C and p53 p.V73fs mu...
Autores principales: | Liu, Ruiqiong, Wei, Wei, Hou, Huaying, Cong, Ping, Zhou, Yong, Yu, Xiaoming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9285856/ https://www.ncbi.nlm.nih.gov/pubmed/35847381 http://dx.doi.org/10.2147/OTT.S362185 |
Ejemplares similares
-
Targeted therapy with anlotinib for patient with recurrent glioblastoma: A case report and literature review
por: Lv, Yajuan, et al.
Publicado: (2019) -
Case Report: Anlotinib Combined With Sintilimab as Third-Line Treatment in a Metastatic Urothelial Bladder Carcinoma Patient With FGFR3 Mutation
por: Cao, Jian-zhou, et al.
Publicado: (2021) -
FGFR2-ERC1: A Subtype of FGFR2 Oncogenic Fusion Variant in Lung Adenocarcinoma and the Response to Anlotinib
por: Hong, Chen, et al.
Publicado: (2022) -
The Function of FGFR1 Signalling in the Spinal Cord: Therapeutic Approaches Using FGFR1 Ligands after Spinal Cord Injury
por: Haenzi, Barbara, et al.
Publicado: (2017) -
Rare Cases of IDH1 Mutations in Spinal Cord Astrocytomas
por: Konovalov, N. A., et al.
Publicado: (2020)